Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surrozen, Inc. (SRZNW for its warrants and SRZN for its common stock) files reports and disclosure documents with the U.S. Securities and Exchange Commission as a public biotechnology company in the biological product manufacturing industry. This SEC filings page brings together those documents so users can review how Surrozen describes its business, capital structure, and material events in official regulatory submissions.
Surrozen’s filings include Form 8-K current reports that outline significant corporate developments. For example, one Form 8-K describes a Sales Agreement with TD Securities (USA) LLC (TD Cowen) that allows Surrozen to offer and sell shares of its common stock in at-the-market offerings under a Form S-3 registration statement. The filing explains that TD Cowen may sell shares on the Nasdaq Capital Market or other existing trading markets, and that Surrozen will pay a commission on gross sales proceeds and provide customary indemnification.
Another Form 8-K details the issuance of a press release announcing Surrozen’s financial results for a specific quarter, categorized under "Results of Operations and Financial Condition." In that report, the company notes that the information, including the press release exhibit, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Such filings help readers understand how Surrozen reports its operating performance and significant events.
On this page, users can access Surrozen’s SEC filings as they are made available through EDGAR, including current reports like Form 8-K, registration statements such as Form S-3, and related exhibits. AI-powered summaries can assist in interpreting key sections, such as descriptions of capital-raising arrangements, warrant and common stock references, and other disclosures about Surrozen’s Wnt pathway-focused biotechnology business.
StemPoint Capital and related parties reported a significant ownership stake in Surrozen, Inc. The Schedule 13G/A shows StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross collectively beneficially owning 619,766 shares of Surrozen common stock, including 329,658 shares issuable upon exercise of warrants.
This represents 7.0% of Surrozen’s common stock, calculated using 8,571,421 shares outstanding as of November 5, 2025, plus specified Series A, B, and E warrants subject to a 9.9% beneficial ownership limitation. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico filed an amended Schedule 13G reporting beneficial ownership of 316,289 shares of Surrozen, Inc. common stock, representing 3.6% of the class as of the reported date.
The stake consists of 113,631 shares of common stock plus 202,658 shares issuable upon exercise of Series A, Series B and Series E warrants, all subject to a 9.9% beneficial ownership limitation. The percentage is based on 8,571,421 shares outstanding as of November 5, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control.
TCG Crossover investment entities increased their indirect stake in Surrozen, Inc. common stock through open-market purchases. On February 11, 2026, TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. each bought 8,882 and 8,881 shares at $23.575 per share, respectively. On February 12, 2026, they bought additional blocks of 547 and 546 shares at $23.8625 per share. After these transactions, one fund reported beneficial ownership of 651,114 shares and the other 651,112 shares, all held indirectly through the TCG Crossover fund structure.
TCG Crossover investment entities reported open-market purchases of Surrozen, Inc. (SRZN) common stock. On January 30, 2026, TCG Crossover Fund II, L.P. bought 2,136 shares at $21.39 and TCG Crossover Fund III, L.P. bought 2,135 shares at $21.39, both indirectly held.
On February 2, 2026, Fund II purchased 366 shares at $21.38 and Fund III purchased 365 shares at $21.38. On February 3, 2026, Fund II bought 2,178 shares at $21.94, bringing its reported indirect holdings to 641,685 shares, while Fund III bought 2,177 shares at $21.94, bringing its reported indirect holdings to 641,682 shares.
TCG Crossover funds and Chen Yu report significant ownership in Surrozen, Inc. common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., through their general partners, each report beneficial ownership of 637,005 shares, or 5.7% of Surrozen’s common stock.
Chen Yu, as sole managing member of both general partners, reports beneficial ownership of 1,274,010 shares, representing 11.4% of the outstanding common stock based on 11,191,978 shares outstanding as of January 27, 2026. The filing states the securities were not acquired or held for the purpose of changing or influencing control of Surrozen.
Surrozen, Inc. reported that board member Shao-Lee Lin, M.D., Ph.D. resigned from its Board of Directors, effective immediately on January 26, 2026. The company stated that Dr. Lin’s resignation was not due to any disagreement regarding Surrozen’s operations, policies, or practices. Surrozen expressed appreciation for her service and dedication to the company’s mission.
Surrozen, Inc. (SRZN) received an initial ownership report showing that investment entities affiliated with TCG Crossover hold significant stakes in its common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., together with their general partners, each report indirect beneficial ownership of 637,005 shares of Surrozen common stock as of 01/26/2026. The funds hold the shares of record, while their general partners and Chen Yu, as sole managing member of each general partner, may be deemed to share voting, investment, and dispositive power over the reported securities.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received an employee stock option grant. On 01/23/2026, he was awarded options to purchase 500 shares of Surrozen common stock at an exercise price of $19.595 per share. These options expire on 01/22/2036 if not exercised.
The 500 options vest over four years in 48 equal monthly installments starting from the grant date, and are held directly by the executive. After this grant, he beneficially owns 500 derivative securities linked to Surrozen common stock.
Surrozen, Inc. received an amended Schedule 13D from venture capital firm The Column Group and related entities detailing their ownership of the company’s common stock. The filing shows that funds affiliated with The Column Group, together with managing partners Tim Kutzkey and Peter Svennilson, beneficially own 3,824,612 shares, or 35.1% of Surrozen’s common stock based on 10,885,617 shares outstanding.
The Column Group III GP, LP is reported as beneficially owning 2,962,544 shares, representing 28.6% of the class, while The Column Group III, LP and The Column Group III-A, LP report stakes of 14.2% and 15.9%, respectively. The Column Group Opportunity III–branded entities each report beneficial ownership of 862,068 shares, or 8.8% of the class.
The amendment also records a series of open-market purchases by TCG III LP and TCG III-A LP between November 13, 2025 and January 20, 2026 at prices ranging from $12.65 to $20.00 per share. Certain additional warrants are excluded from beneficial ownership because they are not exercisable within 60 days of the statement.
Surrozen, Inc. (SRZN) reported insider buying by investment funds affiliated with The Column Group. Multiple Column Group limited partnerships, each a 10% owner, disclosed open‑market purchases of Surrozen common stock on January 15, 16 and 20, 2026.
Examples include The Column Group III, LP buying 5,590 shares at $19.889 and 8,484 shares at $19.5999, and The Column Group III-A, LP buying 6,303 shares at $19.889 and 9,568 shares at $19.5999. Following these purchases, The Column Group III, LP reported beneficial ownership of 900,292 shares, The Column Group III-A, LP reported 1,016,658 shares, and The Column Group Opportunity III, LP reported holding 344,827 shares.
The filing notes that general partners and managing partners associated with these funds may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.